Skip to main content

Table 2 Prognostic value of chemotherapy-associated lymphopenia <0.66 × 10 9 /L for DFS of colorectal cancer

From: The impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer

Variables

Hazard ratio

95% confidence intervals

P-value

Pretreatment albumin

   

≥35 g/L

1.00(ref.)

  

<35 g/L

1.000

0. 592–1. 692

0.999

Pretreatment CEA a

   

<10 ng ml-1

1.00(ref.)

  

≥10 ng ml-1

1. 827

1.040-3.211

0.036

Differentiation

   

Well

1.00(ref.)

  

Moderately

0. 676

0. 292–1.567

0.361

Low

0.882

0.294-2.644

0.823

Sex

   

Male

1.00(ref.)

  

Female

1.018

0.616-1.682

0.946

Age

   

≤49 years

1.00(ref.)

  

50-60 yeas

1.612

0.750-3.465

0.222

>60 years

1.386

0.673-2.854

0.376

Location

   

Rectum

1.00(ref.)

  

Left colon cancer

0.873

0.483-1.576

0.651

Right colon cancer

0.850

0.438-1.649

0.630

Stage

   

II

1.00(ref.)

  

III

2.723

1.549-4.786

0.001

Duration of lymphopenia <1.0 × 10 9 L

   

≤28 days

1.00(ref.)

  

> 28 days

0.556

0.243-1.273

0.165

Chemotherapy-associated lymphocyte counts

   

Lymphocyte counts ≥ 0.66 × 109/L

1.00(ref.)

  

Lymphopenia <0.66 × 109/L

3.521

1.703-7.282

0.001

  1. a Carcinoembryonic antigen.